Biblio

33557 resultats trouvés
R
Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker L-M, Recher C, Ghesquieres H, Morschhauser F, Girault S et al..  2016.  Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. LANCET. 387:2402-2411.
Delfau-Larue M-H, Wolfram K, Berger F, Jardin F, Briere J, Thieblemont C, Feugier P, Haioun C, Salles GAndre, Ribrag V et al..  2014.  Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. BLOOD. 124
Delfau-Larue M-H, Wolfram K, Berger F, Jardin F, Briere J, Thieblemont C, Feugier P, Haioun C, Salles GAndre, Ribrag V et al..  2014.  Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. BLOOD. 124
Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P et al..  2017.  Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. BLOOD. 129:2616-2623.
Lanaret C, Anglicheau D, Vincent A, Lambert C, Couzi L, Buchler M, Ohlmann S, Bertrand D, Jean-Philippe R, Thierry A et al..  2020.  RITUXIMAB FOR RECURRENCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION: RESULTS OF A NATIONWIDE STUDY. NEPHROLOGY DIALYSIS TRANSPLANTATION. 35:2073.
Lanaret C, Anglicheau D, Vincent A, Lambert C, Couzi L, Buchler M, Ohlmann S, Bertrand D, Jean-Philippe R, Thierry A et al..  2020.  RITUXIMAB FOR RECURRENCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION: RESULTS OF A NATIONWIDE STUDY. NEPHROLOGY DIALYSIS TRANSPLANTATION. 35:2073.
Lobbes H, Dervout C, Toussirot E, Felten R, Sibilia J, Wendling D, Gombert B, Ruivard M, Grobost V, Saraux A et al..  2020.  Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. SEMINARS IN ARTHRITIS AND RHEUMATISM. 50:1109-1113.
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel P-A, Mihout F, Dussol B, Matignon M et al..  2017.  Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 28:348-358.
Teisseyre M, Cremoni M, Boyer-Suavet S, Crepin T, Benzaken S, Zorzi K, Esnault V, Brglez V, Seitz-Polski B.  2021.  Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. FRONTIERS IN IMMUNOLOGY. 12:738788.
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, Damaj G, Ribrag V, Feugier P, Casasnovas O et al..  2016.  Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. BLOOD. 128
Le Gouill S., Thieblemont C., Oberic L., Moreau A., Nouabdallah K., Gyan E., Damaj G., Ribrag V., Feugier P., Casasnovas O. et al..  2017.  RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP. HAEMATOLOGICA. 102:4.
Le Gouill S, Thieblemont C, Oberic L, Bouabdallah K, Gyan E, Damaj G, Ribrag V, Bologna S, Gressin R, Casasnovas O et al..  2014.  Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a L. BLOOD. 124
Le Gouill S., Deconinck E., Ghesquieres H., Mertault M., Audhuy B., Jourdan E., Sanhes L., Bouabdallah R., Van Hoof A., Delmer A. et al..  2015.  RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY. HAEMATOLOGICA. 100:387.
Le Gouill S., Deconinck E., Ghesquieres H., Mertault M., Audhuy B., Jourdan E., Sanhes L., Bouabdallah R., Van Hoof A., Delmer A. et al..  2015.  RITUXIMAB MAINTENANCE VERSUS WW AFTER R-DHAP PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED PATIENTS WITH MCL: INTERIM ANALYSIS OF THE LYMA TRIAL, A LYSA STUDY. HAEMATOLOGICA. 100:387.
Morschhauser F., Fowler N.H, Feugier P., Bouabdallah R., Tilly H., Palomba M.L, Fruchart C., Libby E.N, Casasnovas R-O., Flinn I.W et al..  2018.  Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE. 379:934-947.
Audia S., Rossato M., Trad M., Santegoets K., Janikashvili N., Bonnotte B., Radstake T..  2014.  RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA. HAEMATOLOGICA. 99:466–467.
Audia S., Rossato M., Trad M., Santegoets K., Janikashvili N., Bonnotte B., Radstake T..  2014.  RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA. HAEMATOLOGICA. 99:466-467.
Audia S., Rossato M., Trad M., Santegoets K., Janikashvili N., Bonnotte B., Radstake T..  2014.  RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA. HAEMATOLOGICA. 99:466-467.
Tout M., Gagez A.L, Lepretre S., Azzopardi N., Dartigeas C., Mahe B., Ferrand E., Maisonneuve H., Aurran T., Paintaud G. et al..  2016.  Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 30:17.
Tout M., Gagez A.L, Lepretre S., Azzopardi N., Dartigeas C., Mahe B., Ferrand E., Maisonneuve H., Aurran T., Paintaud G. et al..  2016.  Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 30:17.
Pugnet G., Pagnoux C., Terrier B., Perrodeau E., Puechal X., Karras A., Khouatra C., Aumaitre O., Cohen P., Maurier F. et al..  2016.  Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 34:S54-S59.
Pugnet G, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P et al..  2014.  Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life. ARTHRITIS & RHEUMATOLOGY. 66:S780.
Pugnet G, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P et al..  2014.  Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life. ARTHRITIS & RHEUMATOLOGY. 66:S780.
Pugnet G., Pagnoux C., Terrier B., Perrodeau E., Puechal X., Karras A., Khouatra C., Aumaitre O., Cohen P., Maurier F. et al..  2016.  Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 34:S54-S59.
Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaitre O., Cohen P., Maurier F., Decaux O., Ninet J., Gobert P. et al..  2014.  Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. NEW ENGLAND JOURNAL OF MEDICINE. 371:1771-1780.

Pages